

DAFTAR PUSTAKA

1. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE. Heart failure: preventing disease and death worldwide. *ESC Heart Failure* 2014; 1(1):4-25.
2. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nature Reviews Cardiology* 2016; 13(6):368-378.
3. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. Laporan Riskesdas 2013. Hal: 90-91.
4. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *Journal of the American College of Cardiology* 2014; 63(12):1123-1133.
5. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *International Journal of Cardiology* 2014; 171(3):368-376.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola V-P, Jankowska EA. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European heart journal* 2016; 37(27):2129-2200.
7. Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, Cecconi M, Choi DJ, Solal AC, Christ M. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. *Intensive Care Medicine* 2016; 42(2):147-163.
8. Farmakis D, Parissis J, Lekakis J, Filippatos G. Acute heart failure: epidemiology, risk factors, and prevention. *Revista Espanola de Cardiologia* 2015; 68(3):245-248.
9. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. *European heart journal* 2009; 31(7):832-841.
10. Pappas L, Filippatos G. Pulmonary congestion in acute heart failure: from hemodynamics to lung injury and barrier dysfunction. *Revista Espanola de Cardiologia* 2011; 64(09):735-738.

11. Mega JL, Morrow DA. ST-Elevation Myocardial Infarction: Management. In: Mann DL, Zipes DP, Libby P, Bonow RO, eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 10 ed. Philadelphia, USA: Elsevier Saunders; 2014. p. 1059-1154.
12. Felker GM, Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Mann DL, Zipes DP, Libby P, Bonow RO, eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*. 10 ed. Philadelphia, USA: Elsevier Saunders; 2014. p. 484-511.
13. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. *The American journal of medicine* 2006; 119(12):S3-S10.
14. Stevenson LW, Zile M, Bennett TD, Kueffer FJ, Jessup ML, Adamson P, Abraham WT, Manda V, Bourge RC. Chronic ambulatory intracardiac pressures and future heart failure events. *Circulation Heart failure* 2010; 3(5):580-587.
15. Inomata T. Biomarkers: New Horizon for Heart 2 Failure Practice. In: Sato N, ed. *Therapeutic Strategies for Heart Failure*. Tokyo: Springer Japan; 2018. p. 17-38.
16. Vest AR, Jr. FH. Preload. In: Anwaruddin S, Martin JM, Stephens JC, Askari AT, eds. *Cardiovascular Hemodynamics An Introductory Guide*. Philadelphia, USA: Humana Press; 2013. p. 3-27.
17. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. *European heart journal* 2006; 27(3):330-337.
18. Bayes-Genis A, Lopez L, Zapico E, Cotes C, Santalo M, Ordonez-Llanos J, Cinca J. NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. *Journal of cardiac failure* 2005; 11(5):S3-S8.
19. Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLLaboration on Acute decompensated Heart Failure: ELAN-HF Score. *Heart (British Cardiac Society)* 2014; 100(2):115-125.
20. Fonarow GC, Stevenson LW, Steimle AE, Hamilton MA, Moriguchi JD, Walden JA, et al. Persistently high left-ventricular filling pressures predict mortality despite angiotensin-converting enzyme-inhibition in advanced heart failure. *Circulation*. 1994;90:488-488.

21. Fonarow GC. The treatment targets in acute decompensated heart failure. *Reviews in cardiovascular medicine* 2001; 2:S7-S12.
22. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. *Jama* 2005; 294(13):1625-1633.
23. J Romero-Bermejo F, Ruiz-Bailen M, Guerrero-De-Mier M, Lopez-Alvaro J. Echocardiographic hemodynamic monitoring in the critically ill patient. *Current cardiology reviews* 2011; 7(3):146-156.
24. Pozzoli M, Traversi E, Roelandt J. Non-invasive estimation of left ventricular filling pressures by Doppler echocardiography. *European Journal of Echocardiography* 2002; 3(1):75-79.
25. Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type 1. *Journal of the American College of Cardiology* 2012; 60(12):1031-1042.
26. Nikolaou M, Parissis J, Yilmaz MB, Seronde M-F, Kivikko M, Laribi S, Paugam-Burtz C, Cai D, Pohjanjousi P, Laterre P-F. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. *European heart journal* 2013; 34(10):742-749.
27. Nohria A, Tsang SW, Fang JC, Lewis EF, Jarcho JA, Mudge GH, Stevenson LW. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. *Journal of the American College of Cardiology* 2003; 41(10):1797-1804.
28. Stevenson LW. Design of therapy for advanced heart failure. *European journal of heart failure* 2005; 7(3):323-331.
29. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA, Stromberg A, Veldhuisen DJ, Atar D, Hoes AW. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. *European journal of heart failure* 2008; 10(10):933-989.
30. Nieminen MS, Bohm M, Cowie MR, Singer M, Singh S, Tendera M, Thygesen K. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. *European heart journal* 2005; 26(4):384-416.
31. Farmakis D, Parissis J, Filippatos G. Acute heart failure: epidemiology, classification, and pathophysiology. In: Tubaro M, Vranckx P, Price S, Vrints C, eds. *The ESC Textbook of Intensive and Acute Cardiovascular Care*. 2nd ed. Oxford, United Kingdom: Oxford University Press; 2015. p. 459-469.
32. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JEA, Cleland JG, Dickstein K, Drazner MH, Fonarow GC, Jaarsma T. Assessing and

grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. *European journal of heart failure* 2010; 12(5):423-433.

33. Dries DL, Ky B, Wu AHB, Rame JE, Putt ME, Cappola TP. Simultaneous assessment of unprocessed Probnp1-108 in addition to processed Bnp32 improves identification of high-risk ambulatory patients with heart failure. *Circulation Heart failure* 2010; 3(2):220-227.
34. Arrigo M, Parissis JT, Akiyama E, Mebazaa A. Understanding acute heart failure: pathophysiology and diagnosis. *European Heart Journal Supplements* 2016; 18:G11-G18.
35. Ware LB, Matthay MA. Acute pulmonary edema. *New England Journal of Medicine* 2005; 353(26):2788-2796.
36. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *Journal of the American College of Cardiology* 2008; 52(19):1527-1539.
37. Nohria A, Hasselblad V, Stebbins A, Pauly DF, Fonarow GC, Shah M, Yancy CW, Califf RM, Stevenson LW, Hill JA. Cardiorenal interactions: insights from the ESCAPE trial. *Journal of the American College of Cardiology* 2008; 51(13):1268-1274.
38. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. *Journal of the American College of Cardiology* 2009; 53(7):589-596.
39. Verbrugge FH, Dupont M, Steels P, Grieten L, Malbrain M, Tang WHW, Mullens W. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. *Journal of the American College of Cardiology* 2013; 62(6):485-495.
40. Poelzl G, Ess M, Mussner-Seeber C, Pachinger O, Frick M, Ulmer H. Liver dysfunction in chronic heart failure: prevalence, characteristics and prognostic significance. *European journal of clinical investigation* 2012; 42(2):153-163.
41. Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, Elsner S, Sliziuk V, Scherbakov N, Murin Jn. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. *European heart journal* 2016; 37(21):1684-1691.

42. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. *Congestive Heart Failure* 2009; 15(6):256-264.
43. Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. *Journal of the American College of Cardiology* 2008; 52(7):534-540.
44. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *European journal of heart failure* 2012; 14(8):803-869.
45. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. *Congestive Heart Failure* 2009; 15(6):256-264.
46. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *European heart journal* 2016; 37(3):267-315.
47. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno Hc, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *European heart journal* 2017.
48. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O-A, Cleland J, Deharo J-C, Delgado V, Elliott PM. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *European heart journal* 2013; 34(29):2281-2329.
49. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)

Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European heart journal* 2015; 36(41):2793-2867.

50. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European heart journal* 2016; 37(38):2893-2962.
51. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, Gibbs JSR, Huisman MV, Humbert M, Kucher N. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *European heart journal* 2014; 35(43):3033-3080.
52. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. *European journal of heart failure* 2015; 17(6):544-558.
53. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV. Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction. *Heart* 2010; 96(7):533-538.
54. Cox ZL, Lenihan DJ. Loop Diuretic Resistance in Heart Failure: Resistance Etiology-Based Strategies to Restoring Diuretic Efficacy. *Journal of cardiac failure* 2014; 20(8):611-622.
55. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JGF, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F. Decongestion in acute heart failure. *European journal of heart failure* 2014; 16(5):471-482.
56. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO. Diuretic strategies in patients with acute decompensated heart failure. *New England Journal of Medicine* 2011; 364(9):797-805.
57. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, Padley RJ, Huang B, Cohen-Solal A. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on β -blockers in SURVIVE. *European journal of heart failure* 2009; 11(3):304-311.
58. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent J-L. Comparison of dopamine and norepinephrine in the treatment of shock. *New England Journal of Medicine* 2010; 362(9):779-789.
59. Monsieurs KG, Nolan JP, Bossaert LL, Greif R, Maconochie IK, Nikolaou NI, Perkins GD, Soar J, Truhlar A, Wyllie J. European Resuscitation Council guidelines for resuscitation 2015. *Resuscitation* 2015; 95:1-80.

60. Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. *Jama* 2007; 297(12):1332-1343.
61. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *New England Journal of Medicine* 2012; 367(24):2296-2304.
62. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure. *JACC: Heart Failure* 2015; 3(8):647-653.
63. McKie PM, Burnett JC. NT-proBNP: The Gold Standard Biomarker in Heart Failure. *Journal of the American College of Cardiology* 2016; 68(22):2437-2439.
64. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. *Heart* 2006; 92(6):843-849.
65. Volpe M. Natriuretic peptides and cardio-renal disease. *International journal of cardiology* 2014; 176(3):630-639.
66. Kuhn M. Endothelial actions of atrial and B-type natriuretic peptides. *British journal of pharmacology* 2012; 166(2):522-531.
67. Rodeheffer RJ. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? *Journal of the American College of Cardiology* 2004; 44(4):740-749.
68. Richards AM. N-Terminal B-type Natriuretic Peptide in Heart Failure. *Heart Failure Clinics* 2018; 14(1):27-39.
69. Gaggin HK, Januzzi JL. The Use of Biomarkers in the Evaluation of Patients with Heart Failure. In: Mann DL, Felker GM, eds. *Heart Failure: A Companion to Braunwald's Heart Disease*. 3 ed. Philadelphia: Elsevier; 2016. p. 464-481.
70. Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. *JACC: Cardiovascular Imaging* 2009; 2(2):216-225.
71. Baggish AL, van Kimmenade RRJ, Januzzi JL. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. *The American journal of cardiology* 2008; 101(3):S43-S48.

72. Januzzi JL, Rehman S, Mueller T, van Kimmenade RRJ, Lloyd-Jones DM. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. *Clinical chemistry* 2010; 56(12):1814-1821.
73. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola V-P, van Kimmenade R, Pathak A, Mueller T, Metra M. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. *International journal of cardiology* 2013; 168(3):2186-2194.
74. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AHB, Richards M. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. *Journal of the American College of Cardiology* 2010; 55(19):2062-2076.
75. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. PredischARGE B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. *Journal of the American College of Cardiology* 2004; 43(4):635-641.
76. Michtalik HJ, Yeh H-C, Campbell CY, Haq N, Park H, Clarke W, Brotman DJ. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. *The American journal of cardiology* 2011; 107(8):1191-1195.
77. Hartmann F, Packer M, Coats AJS, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD. Prognostic Impact of Plasma N-Terminal Pro - Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure. *Circulation* 2004; 110(13):1780-1786.
78. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. *Clinical chemistry* 2006; 52(8):1528-1538.
79. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. *European heart journal* 2004; 25(4):292-299.
80. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszynska A, Zile MR, DeMets D, Massie BM. Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction. *Circulation: Heart Failure* 2011; 4(1):27-35.

81. Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC. Prognostic implications of changes in N-Terminal pro-B-Type natriuretic peptide in patients with heart failure. *Journal of the American College of Cardiology* 2016; 68(22):2425-2436.
82. Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R. N-terminal pro-B Type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: A 3-Arm, prospective, randomized pilot study. *Journal of the American College of Cardiology* 2010; 55(7):645-653.
83. Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim H-N, Baggish AL, Weiner RB, Chen-Tournoux A. Use of amino-terminal pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. *Journal of the American College of Cardiology* 2011; 58(18):1881-1889.
84. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. *Journal of the American College of Cardiology* 2009; 55(1):53-60.
85. Eurlings LWM, van Pol PEJ, Kok WE, van Wijk S, Lodewijks-Van Der Bolt C, Balk AHMM, Lok DJA, Crijns HJGM, van Kraaij DJW, de Jonge N. Management of chronic heart failure guided by individual N-terminal pro B-type natriuretic peptide targets: results of the PRIMA (Can PRO-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. *Journal of the American College of Cardiology* 2010; 56(25):2090-2100.
86. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure - SIGNAL-HF (Swedish Intervention study - Guidelines and NT-proBNP AnaLysis in Heart Failure). *European journal of heart failure* 2010; 12(12):1300-1308.
87. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J, Sejr Knudsen A, Espersen G, Markenvard J, Egstrup K. Extended heart failure clinic follow-up in low-risk patients: a randomized clinical trial (NorthStar). *European heart journal* 2012; 34(6):432-442.
88. Troughton RW, Frampton CM, Brunner-La Rocca H-P, Pfisterer M, Eurlings LWM, Erntell H, Persson H, O'Connor CM, Moertl D, Karlsto P. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. *European heart journal* 2014; 35(23):1559-1567.

89. Mallick A, Januzzi JL. Biomarkers in Acute Heart Failure. *Revista Espanola de Cardiologia* 2015; 6(68):514-525.
90. Bayes-Genis A, Lopez L, Zapico E, Cotes C, Santalo M, Ordonez-Llanos J, Cinca J. NT-ProBNP Reduction Percentage During Admission for Acutely Decompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. *Journal of cardiac failure* 2005; 11(5):S3-S8.
91. Salah K, Kok WE, Eurlings LW, Bettencourt P, Pimenta JM, Metra M, Bayes-Genis A, Verdiani V, Bettari L, Lazzarini V. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompensated Heart Failure: ELAN-HF Score. *Heart (British Cardiac Society)* 2014; 100(2):115-125.
92. Stienen S, Salah K, Moons AHM, Bakx ALM, Van Pol PE, Schroeder-Tanka JM, Voogel AJ, Keijer JT, Kortz RAM, Dickhoff C. Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-ProBNP target on the reduction of readmission and Mortality rates. *American heart journal* 2014; 168(1):30-36.
93. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *European Journal of Echocardiography* 2016; 17(12):1321-1360.
94. Fontes-Carvalho R, Leite-Moreira A. Heart failure with preserved ejection fraction: fighting misconceptions for a new approach. *Arquivos brasileiros de cardiologia* 2011; 96(6):504-514.
95. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. *Journal of the American College of Cardiology* 1997; 30(6):1527-1533.
96. Nagueh SF, Mikati I, Kopelen HA, Middleton KJ, Quinones MA, Zoghbi WA. Doppler estimation of left ventricular filling pressure in sinus tachycardia. *Circulation* 1998; 98(16):1644-1650.
97. Sohn D-W, Song J-M, Zo J-H, Chai I-H, Kim H-S, Chun H-G, Kim H-C. Mitral annulus velocity in the evaluation of left ventricular diastolic function in atrial fibrillation. *Journal of the American Society of Echocardiography* 1999; 12(11):927-931.
98. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients

with heart failure. *New England Journal of Medicine* 2001; 345(8):574-581.

99. Gheorghiade M, Gattis WA, O'Connor CM, Adams Jr KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. *Jama* 2004; 291(16):1963-1971.
100. Solomonica A, Burger AJ, Aronson D. Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure. *Circulation Heart failure* 2013; 6(1):53-60.
101. Ma TS, Paniagua D, Denktas AE, Jneid H, Kar B, Chan W, Bozkurt B. Usefulness of the sum of pulmonary capillary wedge pressure and right atrial pressure as a congestion index that prognosticates heart failure survival (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). *The American journal of cardiology* 2016; 118(6):854-859.
102. Sastroasmoro S, Ismael S. Dasar-dasar metodologi penelitian klinis. Sagung Seto, Edisi ke-5, Jakarta :CV. Sagung Seto. 2014.
103. Patra P. Sample size in clinical research, the number we need. *International Journal of Medical Science and Public Health* 2012; 1(1):5-9.
104. Bergethon KE, Ju C, DeVore AD, Hardy NC, Fonarow GC, Yancy CW, Heidenreich PA, Bhatt DL, Peterson ED, Hernandez AF. Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the Get With the Guidelines-Heart Failure Registry. *Circulation: Heart Failure* 2016; 9(6):e002594.
105. Davison BA, Metra M, Senger S, Edwards C, Milo O, Bloomfield DM, Cleland JG, Dittrich HC, Givertz MM, O'Connor CM. Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. *European journal of heart failure* 2016; 18(8):1041-1050.
106. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, De Ferranti S, Despres J-P, Fullerton HJ, Howard VJ. Executive summary: heart disease and stroke statistics - 2015 update. *Circulation* 2018; 131(4):434-441.
107. Tuppin P, Cuerq A, de Peretti C, Fagot-Campagna A, Danchin N, Juillière Y, Alla F, Allemand H, Bauters C, Drici M-D. Two-year outcome of patients after a first hospitalization for heart failure: A national observational study. *Archives of cardiovascular diseases* 2014; 107(3):158-168.
108. Khazanie P, Heizer GM, Hasselblad V, Armstrong PW, Califf RM, Ezekowitz J, Dickstein K, Levy WC, McMurray JJV, Metra M. Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of

Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. *American heart journal* 2015; 170(2):290-297. e291.

109. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JoP, Marques I, Schroeder-Tanka JM, Keijer JT. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). *Circulation* 2018; 137(16):1671-1683.
110. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, Smiseth OA, Guazzi M, Lam CSP, Maggioni AP. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. *European heart journal* 2014; 35(40):2797-2815.
111. Ferrari R, Bohm M, Cleland JGF, Paulus WJS, Pieske B, Rapezzi C, Tavazzi L. Heart failure with preserved ejection fraction: uncertainties and dilemmas. *European journal of heart failure* 2015; 17(7):665-671.
112. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XHT, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. *Journal of the American College of Cardiology* 2012; 59(11):998-1005.
113. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VrL. Death in heart failure: a community perspective. *Circulation: Heart Failure* 2008; 1(2):91-97.
114. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozd J. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. *European journal of heart failure* 2013; 15(10):1173-1184.
115. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL. Spironolactone for heart failure with preserved ejection fraction. *New England Journal of Medicine* 2014; 370(15):1383-1392.
116. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *The Lancet* 2012; 380(9851):1387-1395.

117. Fukuta H, Goto T, Wakami K, Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. *European journal of preventive cardiology* 2016; 23(1):78-85.
118. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. *Cochrane Database Syst Rev* 2012;2:CD003838.
119. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. *International journal of cardiology* 2002; 82(2):149-158.
120. DeVore AD, Hasselblad V, Mentz RJ, O'Connor CM, Armstrong PW, McMurray JJ, Ezekowitz JA, Tang WHW, Starling RC, Voors AA. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCENDâ€• HF. *European journal of heart failure* 2015; 17(3):340-346.
121. Muneer K, Nair A. Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies. *Indian Heart Journal* 2017; 69(3):371-374.
122. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozd J. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. *European journal of heart failure* 2013; 15(10):1173-1184.
123. Poole-Wilson PA. The Cardiac Insufficiency Bisoprolol Study II. *Lancet (London, England)* 1999; 353(9161):1360-1361
124. Willenheimer R. How to begin treatment in chronic heart failure? Results of CIBIS III. *European Heart Journal Supplements* 2006; 8(suppl_C):C43-C50.
125. Willenheimer R, Erdmann E, Follath F, Krum H, Ponikowski P, Silke B, Van Veldhuisen DJ, Van De Ven L, Verkenne P, Lechat P. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. *European journal of heart failure* 2004; 6(4):493-500.